On Monday, Sangamo Therapeutics Inc (NASDAQ: SGMO) opened lower -3.61% from the last session, before settling in for the closing price of $0.46. Price fluctuations for SGMO have ranged from $0.41 to $3.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.57%. Company’s average yearly earnings per share was noted 38.88% at the time writing.
Let’s determine the extent of company efficiency that accounts for 183 employees. In terms of profitability, gross margin is 97.68%, operating margin of -76.91%, and the pretax margin is -77.72%.
Sangamo Therapeutics Inc (SGMO) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Sangamo Therapeutics Inc is 3.17%, while institutional ownership is 22.05%.
Sangamo Therapeutics Inc (SGMO) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 0.04 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.04) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 38.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.02% during the next five years compared to 10.57% growth over the previous five years of trading.
Sangamo Therapeutics Inc (NASDAQ: SGMO) Trading Performance Indicators
Check out the current performance indicators for Sangamo Therapeutics Inc (SGMO). In the past quarter, the stock posted a quick ratio of 1.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.29 in one year’s time.
Technical Analysis of Sangamo Therapeutics Inc (SGMO)
Looking closely at Sangamo Therapeutics Inc (NASDAQ: SGMO), its last 5-days average volume was 7.06 million, which is a jump from its year-to-date volume of 6.08 million. As of the previous 9 days, the stock’s Stochastic %D was 10.61%.
During the past 100 days, Sangamo Therapeutics Inc’s (SGMO) raw stochastic average was set at 5.66%, which indicates a significant decrease from 7.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0548 in the past 14 days, which was lower than the 0.0590 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5135, while its 200-day Moving Average is $1.0973. However, in the short run, Sangamo Therapeutics Inc’s stock first resistance to watch stands at $0.4669. Second resistance stands at $0.4935. The third major resistance level sits at $0.5169. If the price goes on to break the first support level at $0.4169, it is likely to go to the next support level at $0.3935. Should the price break the second support level, the third support level stands at $0.3669.
Sangamo Therapeutics Inc (NASDAQ: SGMO) Key Stats
There are currently 233,167K shares outstanding in the company with a market cap of 132.87 million. Presently, the company’s annual sales total 57,800 K according to its annual income of -97,940 K. Last quarter, the company’s sales amounted to 6,440 K and its income totaled -30,600 K.
